Cypherpunk Technologies (CYPH) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cypherpunk Technologies (CYPH) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 274.7% versus a loss of 22.4%. Over five years, RCKT leads with a -90.6% price change compared with -91.1% for CYPH. Cypherpunk Technologies is the larger company by market cap ($316.8 million vs $281.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYPH | RCKT |
|---|---|---|
| Share price | $2.94 | $2.56 |
| Market cap | $316.83M | $281.02M |
| 1-day change | +4.63% | -2.66% |
| YTD return | +142.24% | -25.07% |
| 1-year return | +274.67% | -22.42% |
| 5-year return | -91.08% | -90.58% |
| P/E ratio (TTM) | 4.67 | — |
| EPS (TTM) | $0.63 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.19 | $5.45 |
| 52-week low | $0.393 | $2.42 |
| Distance from 52-week high | -29.83% | -53.03% |
| Analyst consensus | none | buy |
| Avg. price target upside | +66.67% | +232.03% |
| Average volume | 10.07M | 1.67M |
| Shares outstanding | 107.76M | 109.77M |
| Employees | 6 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYPH has outperformed RCKT by 297.1 percentage points over the past year.
About Cypherpunk Technologies
CYPH stock →Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
CYPH vs RCKT FAQ
Which is bigger, Cypherpunk Technologies or Rocket Pharmaceuticals?
Cypherpunk Technologies (CYPH) is larger, with a market capitalization of $316.83M compared with $281.02M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, CYPH or RCKT?
CYPH returned +274.67% over the past 12 months, compared with -22.42% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are Cypherpunk Technologies and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.